ANTHEM / Q3-FY26 / claim-ledger

Audit the questions that mattered.

Anthem Biosciences · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ3-FY26 · 2026-01-15Back to quarter ↗

Questions audited

Answered directly

63%

Numeric claims

Consistency

contradicted

Question ledger

What was answered, and how?

Vivek Agarwal · City Group

partial

Full year revenue and margin guidance status after 9 months performance.

revenue growth estimate of about 20% with EBITDA margins remaining constant... we should be looking at a good quarter four... revenue growth will be in the mid-teens around 15 to 16%... margin guidance of 20% plus on EBITDA remains intact

Vivek Agarwal · City Group

evasive

Structural margin expansion sustainability into FY27 and FY28.

our aspiration is always to have the margin trend pointing north... material margin we want to move trend north... we would want to keep our margin steady though aspiration wise we want to grow

Vivek Agarwal · City Group

partial

Revenue slowdown due to product disruption and recovery timeline.

many companies have destocked a little bit and rationalized their stocks... that will be corrected in the subsequent year... we continue to add more customers... very positive about FY27 and 28

Shreyans Mukharji · Nomura

evasive

Expectation of 20% growth in FY27 and key growth drivers.

tough question to answer... I can't say till I'm a little bit into that year... directionally we are looking northwards... in the next 5 years will we have a CAGR of what we've had in the last 5 years? I expect so.

Shreyans Mukharji · Nomura

evasive

Relative importance of growth drivers: existing products, new launches, lateral contracts.

all of the above... commercial products still have headroom... new products will be slower to take off... lateral contracts yielding fruits... can't predict at this point

Shreyans Mukharji · Nomura

direct

Full impact of backward integration on gross margin and sustainability.

the full impact is there because we don't source the intermediate anymore from China... outsourcing is nil right now... this level of margin should sustain

Bansi Desai · JP Morgan

direct

Pipeline update: early phase, phase 2, phase 3 molecule counts and progression.

early phase molecules still similar numbers about 130 to 140... phase 2 programs about five or six could move to phase 3 in next 18-30 months... phase 3 numbers remain the same at six

Bansi Desai · JP Morgan

direct

Impact of improved biotech funding on pipeline expansion.

we are seeing an improvement in environment, many requests for RFQs have come in last one quarter... it is turning around

Bansi Desai · JP Morgan

partial

Semaglutide API opportunity post-patent expiry and competitive positioning.

we are among the very few who are completely backward integrated... we are arguably the most backward integrated company in the country... we see a very good play in it

Pamela · GM Financial

direct

Capacity utilization across units and adequacy for 20% growth.

unit one 75% occupancy... unit two 35% utilized... unit three underutilized... we have decent capacity to continue on the growth path

Karthik Ban · Bajaj Life Insurance

direct

Capex milestones and bottlenecks for unit 4.

civil work is ongoing... towards March 27 financial year we'll have major portion of capex going out... it's still in early stage civil work mode

Sanjay Kumar · Ith Thoughts PMS

direct

Semaglutide focus: oral vs injectable, DMF filing, customer signings.

we focus on semaglutide as the active... we have signed up with a bunch of customers in India... we haven't filed the DMF though we are in a position to do it